![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Energy Bear 2X Shares
ERY
Direxion Daily Financial Bull 3X Shares ETF
FAS
4
iShares Biotechnology ETF
IBB
5
iShares US Home Construction ETF
ITB
US Stock MarketDetailed Quotes
Valneva (VALN)
- 5.272
- +0.102+1.98%
Trading Jun 30 15:36 ET
499.93MMarket Cap-2.88P/E (TTM)
5.540High5.120Low31.72KVolume5.270Open5.170Prev Close167.82KTurnover0.04%Turnover RatioLossP/E (Static)94.82MShares12.25052wk High5.71P/B412.75MFloat Cap5.04052wk Low--Dividend TTM78.29MShs Float67.840Historical High--Div Yield TTM8.12%Range %3.620Historical Low5.291Avg Price1Lot Size
VALN Stock Chart
Real-Time
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
VALN Orderflow
Unit: --
VALN Orderflow Trend
IntradayDayWeekMonth
No Data
Valneva (VALN) News
European Medicines Agency Panel Recommends Change to Valneva's Chikungunya Vaccine Marketing Approval
Valneva Shareholders Back All AGM Resolutions as Board Elects New Chair
Press Release: Valneva Announces Successful Outcome of Its Annual General Meeting
Valneva Files to Sell 31.79M Ordinary Shares for Holders
Valneva Announces Availability of Documentation for Its Annual General Meeting
VALNEVA:Declaration of Shares and Voting Rights - Status as of May 31, 2026
Valneva (VALN) Stock Forum
$Valneva (VALN.US)$
tmr is the day
tmr is the day
$Valneva (VALN.US)$
accumulating!!!!
accumulating!!!!
$Valneva (VALN.US)$
accumulating or traps ?
accumulating or traps ?
$Valneva (VALN.US)$ $Pfizer (PFE.US)$ Pfizer, Valneva Report Topline Results From Phase 3 VALOR Clinical Trial Of Investigational 6-Valent OspA-Based Lyme Disease Vaccine Candidate PF-0730740; Trial Shows More Than 70% Efficacy In Preventing Lyme Disease In Individuals Aged Five Years And...
Benzinga
Pfizer, Valneva Report Topline Results From Phase 3 VALOR Clinical Trial Of Investigational 6-Valent OspA-Based Lyme Disease Vaccine Candidate PF-0730740; Trial Shows More Than 70% Efficacy In Prev...
Benzinga
Pfizer, Valneva Report Topline Results From Phase 3 VALOR Clinical Trial Of Investigational 6-Valent OspA-Based Lyme Disease Vaccine Candidate PF-0730740; Trial Shows More Than 70% Efficacy In Prev...
1
$Valneva (VALN.US)$ Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ
GlobeNewswire
01:00
Long-lasting antibody persistence was comparable in older (65+) and younger adults
Long-term antibody persistence is a key competitive advantage
for a vaccine targeting unpredictable outbreak diseases like chikungunya
Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positiv...
GlobeNewswire
01:00
Long-lasting antibody persistence was comparable in older (65+) and younger adults
Long-term antibody persistence is a key competitive advantage
for a vaccine targeting unpredictable outbreak diseases like chikungunya
Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positiv...
3
8
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)